Severe rosacea in a patient on infliximab for ulcerative colitis: pathophysiological considerations.
Kosmidou
Maria
M
Gaitanis
Georgios
G
Nomikos
Katon
K
Zioga
Aikaterini
A
Katsanos
Konstantinos
K
Bassukas
Ioannis D
ID
Tsianos
Epameinondas
E
D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001706:Biopsy; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use; D012393:Rosacea / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D005765:Gastrointestinal Agents; D011433:Propranolol; D000069285:Infliximab; D004318:Doxycycline